http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Jan 2025 09:22:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Press+Releases/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html <ul class="bwlistsquare"> <li> <i>Consolidates ownership of listeria monocytogenes-based immunotherapy IP</i> </li> <li> <i>Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications</i> </li> <li> <i>Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma</i> </li> <li> <i>Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 &amp; precludes raises below $12.00 for 6 months</i> </li> <li> <i>Karim Galzahr appointed to OS Therapies Board of Directors</i> </li> </ul> <p> NEW YORK--(BUSINESS WIRE)-- OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into http://www.streetinsider.com/Business+Wire/OS+Therapies+Agrees+to+Acquire+All+Listeria+Monotygenes-based+Immuno-Oncology+Programs+and+IP+Assets+from+Ayala+Pharmaceuticals%2C+Adding+Phase+2+Lung+Cancer+and+Phase+1+Prostrate+Cancer+Programs+to+Pip/24263914.html Wed, 29 Jan 2025 09:22:00 -0500 A.06822034 A.40538608 ADXS O.16070989 O.20026344 O.47615966 OSTX http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Ayala+Pharmaceuticals%2C+++++++++++++++/23202290.html si-local-file:///var/storage/secattach/20240509/23202290.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Ayala+Pharmaceuticals%2C+++++++++++++++/23202290.html Thu, 09 May 2024 16:07:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Ayala+Pharmaceuticals%2C+++++++++++++++/23202290.html si-local-file:///var/storage/secattach/20240509/23202290.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Ayala+Pharmaceuticals%2C+++++++++++++++/23202290.html Thu, 09 May 2024 16:07:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23129197.html si-local-file:///var/storage/secattach/20240426/23129197.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23129197.html Fri, 26 Apr 2024 17:04:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23129197.html si-local-file:///var/storage/secattach/20240426/23129197.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23129197.html Fri, 26 Apr 2024 17:04:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ayala+Pharmaceuticals%2C++++For%3A+Mar+25/23088166.html si-local-file:///var/storage/secattach/20240419/23088166.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ayala+Pharmaceuticals%2C++++For%3A+Mar+25/23088166.html Fri, 19 Apr 2024 07:51:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ayala+Pharmaceuticals%2C++++For%3A+Mar+25/23088166.html si-local-file:///var/storage/secattach/20240419/23088166.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ayala+Pharmaceuticals%2C++++For%3A+Mar+25/23088166.html Fri, 19 Apr 2024 07:51:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23073969.html si-local-file:///var/storage/secattach/20240416/23073969.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23073969.html Tue, 16 Apr 2024 16:12:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23073969.html si-local-file:///var/storage/secattach/20240416/23073969.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Ayala+Pharmaceuticals%2C++++For%3A+Dec+31/23073969.html Tue, 16 Apr 2024 16:12:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068155.html si-local-file:///var/storage/secattach/20240415/23068155.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068155.html Mon, 15 Apr 2024 16:35:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068155.html si-local-file:///var/storage/secattach/20240415/23068155.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068155.html Mon, 15 Apr 2024 16:35:00 -0500 ADXS O.02269150 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068162.html si-local-file:///var/storage/secattach/20240415/23068162.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Ayala+Pharmaceuticals%2C+++++++++++++++/23068162.html Mon, 15 Apr 2024 16:35:00 -0500 ADXS O.02269150